Stockwatch: A Week Of Dashed Expectations

Last week was another losing week in broad stock markets, driven by fears of a Brexit. The S&P 500 index was depressed by about 1% and in what is becoming an unwelcome recent trend, the NASDAQ Biotech index (NBI) underperformed the broad stock market by finishing the week down over 4%. While some of this underperformance can be attributed to risk-aversion at a time of short-term macroeconomic uncertainty, missed expectations in life science companies did not help matters.

stock

Having come a long way (down) since the peak of last summer, investors are interested in when life science stocks will stabilize, and then when they will start to outperform broad stock markets again. Technical analysts or chartists look at share price graphs and pronounce some meaning from the patterns. However, I tend think of technical analysts in the same way as Robert Harris’ character Cicero (in his historical fiction series on ancient Rome) thought of the auguries and soothsayers of the day. To bring Cicero’s quote up to date, no doubt birds and entrails have their place in civilian government, but they sit badly with the prediction of stock market trends.

When the sector renaissance occurs, it will be when the positive fundamental drivers of the sector – new blockbuster product...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

MBX Surges As Phase II Data Show Competitive Profile For Canvuparatide

 
• By 

MBX Biosciences reported Phase II results for once-weekly canvuparatide that showed comparable efficacy to Ascendis Pharma’s once-daily Yorvipath for hypoparathyroidism.

Ionis Targets Ultra-Rare Disease Market With Zilganersen

 

The biotech announced positive topline results from its pivotal study in Alexander disease, which has an estimated population of about 300 in the US.

EADV: UCB’s Bimzelx Primed To Maintain Pole Position in HS

 
• By 

The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

More from R&D

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

Pipeline Watch: Six Approvals And Twenty Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

QL Biopharm’s Zovaglutide Offers Potentially Safer Once-Monthly Obesity Option

 

Zovaglutide tied Amgen’s MariTide in weight reduction at Week 24 in a Phase II study, but with a potentially better safety profile. However, efficacy versus existing once-weekly drugs is a remaining question.